证券代码：300813 证券简称：泰林生物 公告编号：2025-038 （1）本项目用地需按照国家现行法律法规及地方政策规定的用地程序办理， 通过招标、拍卖或挂牌出让方式取得，土地使用权能否竞得、土地使用权的最终 成交价格及取得时间存在不确定性。 （2）本项目尚需发改、环保等部门审批，存在不确定性；本项目的各项数 据均为初步规划数据，不代表公司对未来盈利的任何预测或承诺，最终实际投资 金额具有不确定性。 （3）本项目建设、投产及生产经营需要一定的时间，存在一定的不确定性， 浙江泰林生物技术股份有限公司 关于与杭州富春湾新城管理委员会签订高性能过滤器及配 套功能膜产业化项目合同书暨对外投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 浙江泰林生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第七次会议、第四届监事会第七次会议，于 2025 年 5 月 19 日召开 2024 年年度股东大会，审议通过了《关于拟与杭州富春湾新城管理委员 会签订高性能过滤器及配套功能膜产业化项目合同书的议案》。具 ...

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, and process analysis, providing high-quality products and solutions for the biopharmaceutical, healthcare, food and beverage, and environmental protection industries [2] Financial Performance - For Q1 2025, the company reported revenue of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a gross profit margin of 49.27% [2] Market Position - As of May 19, the company's stock closed at 19.1 yuan, up 3.52%, with a rolling PE ratio of 216.23, marking a new low in 29 days. The total market capitalization is 2.315 billion yuan [1] - The average PE ratio in the medical device industry is 49.26, with a median of 36.71, placing Tailin Biological at the 117th position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders is 11,553, a decrease of 294 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

长城证券股份有限公司 关于浙江泰林生物技术股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐机构名称：长城证券股份有限公司 被保荐公司简称：泰林生物 | | | | | --- | --- | --- | --- | | 保荐代表人姓名：白毅敏 联系电话：0755-83516222 | | | | | 保荐代表人姓名：严绍东 联系电话：0755-83516222 | | | | | 现场检查人员姓名：严绍东、陈诗瑶 | | | | | 现场检查对应期间：2024 年度 | | | | | 现场检查时间：2025 年 4 月 24 日、2025 年 5 月 日 | 13 | | | | 一、现场检查事项 现场检查意见 | | | | | （一）公司治理 是 | | 否 | 不适 | | | | | 用 | | 现场检查手段：查阅最新公司章程、公司治理各项制度、股东大会、董事会和监 | | | | | 事会的全套会议资料；查看公司主要经营场所；访谈公司管理层，了解公司基本 制度的执行情况，了解公司与关联企业在人员、资产、财务、机构、业务等方面 | | | | | 是否存在影响独立性的情形，核查是否存在 ...

2024年度持续督导跟踪报告 | 保荐机构名称：长城证券股份有限公司 | 被保荐公司名称：浙江泰林生物技术股份有 | | --- | --- | | | 限公司 | | 保荐代表人姓名：白毅敏 | 联系电话：0755-83516222 | | 保荐代表人姓名：严绍东 | 联系电话：0755-83516222 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 限于防止关联方占用公司资源的制度、募集资金管 | | | | 是 | | 理制度、内控制度、内部审计制度、关联交易制 | | | 度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 按月查询，每月一次 | | （2）公司募集资金项目进展是否与信息披露文件 | | | 一致 | 是 | | 4 ...

长城证券股份有限公司关于 | 名称 | 长城证券股份有限公司 | | | | | --- | --- | --- | --- | --- | | 法定代表人 | 王军 | | | | | 注册地址 | 深圳市福田区福田街道金田路 | 2026 号能源大厦南塔楼 | 10-19 | 层 | | 办公地址 | 深圳市福田区福田街道金田路 | 2026 号能源大厦南塔楼 | 10-19 | 层 | 浙江泰林生物技术股份有限公司 2021 年向不特定对象发行可转换公司债券 持续督导保荐总结报告书 浙江泰林生物技术股份有限公司（ 以下简称（ 泰林生物"、（ 公司"、（ 发 行人"或（ 上市公司"）2021 年度向不特定对象发行可转换公司债券于 2022 年 1 月 19 日在深圳证券交易所发行上市，持续督导期至 2024 年 12 月 31 日止。长 城证券股份有限公司（ 以下简称（ 长城证券"、（ 保荐机构"）作为此次发行的 保荐机构，于股票上市之日起对公司进行持续督导工作。截至目前，持续督导期 已满，现根据（ 证券发行上市保荐业务管理办法》 深圳证券交易所创业板股票 上市规则》 深圳证券交易所上市公司自律监管指引第 ...

Group 1: Market Position and Competitive Advantage - The company has a strong technical advantage in the field of microbial detection and control, providing various equipment, instruments, and consumables [1] - The company aims to enhance its market share and competitive edge in the food, pharmaceutical, and cosmetics industries through increased market development efforts and diversified strategies [2] - The company plans to expand its overseas market presence to mitigate local risks and enhance existing product applications and market share [2] Group 2: Financial Performance and Growth Prospects - The company reported its profitability for 2024 and Q1 2025 in its disclosed periodic reports [2] - The company anticipates growth in profitability by leveraging its R&D and product innovation capabilities, accelerating new product development, and expanding existing product applications [2] - In 2024, the company's R&D investment is projected to account for 17.86% of its operating revenue [2] Group 3: Industry Outlook - The pharmaceutical equipment manufacturing industry is a key area for national support in promoting independent innovation and industrial upgrading [2] - Recent government policies have been introduced to support domestic biopharmaceutical companies in enhancing drug innovation capabilities and expanding application scenarios in the biopharmaceutical industry [2]

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures in the life sciences sector [2] - The company provides high-quality products and solutions for industries such as biomedicine, healthcare, food and beverage, and environmental protection [2] Financial Performance - For Q1 2025, the company reported revenue of 66.94 million yuan, a year-on-year decrease of 16.33% [2] - The net profit for the same period was 3.53 million yuan, down 39.93% year-on-year, with a sales gross margin of 49.27% [2] Market Position - As of May 6, the company's stock closed at 17.95 yuan, up 2.69%, with a rolling price-to-earnings (PE) ratio of 203.21, marking a new low in 20 days [1] - The average PE ratio in the medical device industry is 48.90, with a median of 36.41, placing Tailin Biological at the 116th position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders for Tailin Biological was 11,553, a decrease of 294 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

证券代码：300813 证券简称：泰林生物 公告编号：2025-035 浙江泰林生物技术股份有限公司 关于 2025 年员工持股计划非交易过户完成暨回购股份处理 完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）于 2025 年 3 月 11 日 召开第四届董事会第六次会议、第四届监事会第六次会议，并于 2025 年 3 月 27 日召开 2025 年第一次临时股东大会，审议通过了《关于公司〈2025 年员工持股 计划（草案）〉及其摘要的议案》《关于公司〈2025 年员工持股计划管理办法〉的 议案》等相关议案。具体内容详见公司在巨潮资讯网（http://www.cninfo.com.cn） 披露的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定，现将 公司 2025 年员工持股计划（以下简称"本员工持股计划"）实施进展情况公告 如下： 一、本员工持股计划的股票来源及数量 本员工持股计划股票来源为公司股份回 ...

Core Viewpoint - TaiLin Bio's revenue for 2024 is 349 million, an increase of 29.33%, while net profit decreased by 33.65% [2][3]. Financial Performance - Total revenue for 2024 reached 349,998,253.03 yuan, up from 269,856,059.81 yuan in 2023, marking a growth of 29.33% [3]. - Net profit attributable to shareholders was 13,050,671.23 yuan, down from 19,668,950.46 yuan in 2023, a decline of 33.65% [3]. - Deducting non-recurring gains and losses, net profit was 6,680,101.87 yuan, a decrease of 40.55% compared to 2023 [3]. - Operating cash flow net amount was 24,656,614.19 yuan, an increase of 1,176.30% year-on-year [2][3]. - Basic earnings per share were 0.12 yuan, down from 0.18 yuan in 2023, a decline of 33.33% [3]. Revenue Breakdown - The pharmaceutical industry accounted for 314,245,411.71 yuan, representing 90.04% of total revenue, with a year-on-year growth of 32.97% [6]. - Revenue from the sterile production and contamination control equipment series was 164,121,071.60 yuan, showing the highest growth of 52.56% [4][6]. - Microbial detection technology series products generated 124,593,032.95 yuan, accounting for 35.70% of total revenue, with a growth of 17.15% [4][6]. - Organic analysis instruments series products contributed 25,531,307.16 yuan, representing 7.32% of total revenue, with a growth of 14.05% [4][6]. Geographic Performance - Domestic revenue was 324,965,505.54 yuan, accounting for 92.83% of total revenue, with a year-on-year increase of 31.49% [5][6]. - International revenue was 25,032,747.49 yuan, showing a growth of 11.52% [5][6]. Future Strategy - The company aims to focus on the life and health industry, emphasizing technology-driven development and establishing a scientific R&D management system [8]. - Plans include accelerating the transition to smart manufacturing and expanding overseas market share [8].